A board asks for the competitive read before the meeting, not after. AXLRx delivers evidence-led competitive, patient and payer intelligence, scoped to your asset, verified against a live source, in 72 hours.
A syndicated report describes the market. An AXLRx brief frames the decisions your launch team has to make on positioning, on access, and on where to compete. Every section answers a named commercial question, scoped to your asset and proposed label, not the category in aggregate.
And every figure is verified against a live source at the point of writing. If it can't be sourced, it doesn't appear.
Four things hold across every brief: evidence-backed, built on consulting methodology, reviewed by a practising consultant, and delivered decision-ready — not a data dump you still have to interpret.
Every figure clears these checks before delivery.
Every claim is cited to a live PMID, ClinicalTrials.gov ID or URL at the point of writing. Uncited claims are dropped, not estimated.
PubMed metadata is fetched live during authoring. Model memory mis-attributes authors and journals even on correct identifiers.
The figure must appear in the cited source, not merely be consistent with it. An independent audit pass then re-checks every link before delivery.
A fourth check, after the first three: every brief is read by a pharma commercial consultant before it ships, not released straight from a model.
Drug, mechanism, indication, target cohort, geography — five minutes.
We confirm scope, clarify open questions and lock the delivery window.
A decision-structured PDF, an editable Excel model and an optional deck — with a readout call.
Your team has the brief in 72 hours. Scope confirmation takes one call.